Palvella Therapeutics, Inc. Files 8-K, Confirms Name Change

Ticker: PVLA · Form: 8-K · Filed: Sep 3, 2025 · CIK: 1583648

Palvella Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyPalvella Therapeutics, Inc. (PVLA)
Form Type8-K
Filed DateSep 3, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: name-change, corporate-action

Related Tickers: PIRS

TL;DR

Pieris Pharmaceuticals is now Palvella Therapeutics, Inc. as of Dec 13, 2024.

AI Summary

On September 3, 2025, PALVELLA THERAPEUTICS, INC. (formerly Pieris Pharmaceuticals, Inc.) filed an 8-K report. The filing indicates a name change from Pieris Pharmaceuticals, Inc. to Palvella Therapeutics, Inc. effective December 13, 2024. The company is incorporated in Nevada and its fiscal year ends on December 31.

Why It Matters

This filing officially documents the corporate name change, which is important for investors and stakeholders to accurately identify the company in official records and communications.

Risk Assessment

Risk Level: low — The filing is a routine administrative update regarding a name change and does not involve any new financial or operational risks.

Key Players & Entities

  • PALVELLA THERAPEUTICS, INC. (company) — Registrant
  • Pieris Pharmaceuticals, Inc. (company) — Former name
  • September 3, 2025 (date) — Date of Report
  • December 13, 2024 (date) — Effective date of name change
  • Nevada (jurisdiction) — State of incorporation

FAQ

What was the previous name of Palvella Therapeutics, Inc.?

The previous name was Pieris Pharmaceuticals, Inc.

When did the name change become effective?

The name change became effective on December 13, 2024.

What is the exact name of the registrant as specified in its charter?

The exact name of the registrant is PALVELLA THERAPEUTICS, INC.

In which state is Palvella Therapeutics, Inc. incorporated?

Palvella Therapeutics, Inc. is incorporated in Nevada.

What is the filing date of this 8-K report?

The filing date of this 8-K report is September 3, 2025.

Filing Stats: 516 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2025-09-03 07:31:18

Key Financial Figures

  • $0.001 — e on which registered Common stock, $0.001 par value per share PVLA The Nasdaq

Filing Documents

01

Item 7.01 Regulation FD Disclosure. On September 3, 2025, Palvella Therapeutics, Inc. (the " Company ") posted a corporate presentation to its website, which representatives of the Company will use in various meetings with investors from time to time. A copy of the presentation is furnished herewith as Exhibit 99.1, and incorporated herein by reference. The information furnished pursuant to Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Document 99.1 Corporate Presentation of Palvella Therapeutics, Inc., dated September 3, 2025* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) *Furnished herewith

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PALVELLA THERAPEUTICS, INC. Date: September 3, 2025 By: /s/ Matthew Korenberg Matthew Korenberg Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.